代谢和减重手术与肥胖症药物治疗预防癌症：现状与未来可能。
Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities.
机构信息
Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, UT, USA.
Cancer Control and Population Sciences Program, Huntsman Cancer Institute, Salt Lake City, UT, USA.
出版信息
J Natl Cancer Inst Monogr. 2023 May 4;2023(61):68-76. doi: 10.1093/jncimonographs/lgad003.
Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.
肥胖是一种慢性、复发性、进行性的肥胖症，会增加至少 13 种癌症的发病风险。本报告简要回顾了代谢和减重手术以及与癌症风险相关的肥胖药物治疗方面的科学现状。队列研究的荟萃分析报告称，与非手术肥胖治疗相比，代谢和减重手术与较低的癌症发病风险独立相关。关于肥胖药物治疗的抗癌作用知之甚少。最近肥胖药物的批准和有前途的研发管线将提供机会，以了解肥胖症治疗作为一种基于证据的癌症预防策略的潜力。有无数的研究机会可以促进我们对代谢和减重手术以及肥胖药物治疗如何用于癌症预防的理解。
Zotero 插件